Chronic Lymphocytic Leukemia Articles & Analysis
6 articles found
A major breakthrough occurred with the FDA approval of Venetoclax (ABT-199), a BCL2-selective inhibitor used in the treatment of chronic lymphocytic leukemia (CLL). Venetoclax works by mimicking BH3-only proteins, thereby displacing pro-survival BCL2 proteins and triggering apoptosis in cancer cells. In 2020, a study published in the New ...
These engineered T cells selectively recognize and eliminate CD19-positive B cells. 2) Chronic Lymphocytic Leukemia (CLL): In CLL, a type of chronic lymphocytic leukemia, the majority of patients display CD19 on the surface of leukemia cells. ...
ACCC just launched updates to the MRD Testing Implementation Roadmap, which aims to help multidisciplinary providers successfully integrate MRD testing into the cancer care continuum for patients with Chronic Lymphocytic Leukemia (CLL) and multiple myeloma, complementing the Roadmap for patients with B-cell acute lymphoblastic ...
Shannon Fatigante (Talent Acquisition Senior Program Manager) has a father currently fighting chronic lymphocytic leukemia (CLL). Shannon: When my dad called me last summer, he very calmly shared that his recent bloodwork had revealed that he had cancer – specifically CLL. ...
Purpose:Although considerable progress has been made withautologous T cell–based therapy in B-cell malignancies, appli-cation in chronic lymphocytic leukemia (CLL) lags behind dueto disappointing response rates as well as substantial toxicitythat is of particular concern in the elderly CLL population.Vg9Vd2-T cells form a conserved T-cell ...
The PRISMS study aims to enroll 222 patients undergoing chemotherapy for chronic lymphocytic leukemia (CLL), Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma (NHL) in two Australian hospitals. ...